MCL1 and breast carcinoma: Thus, at appropriate dosing regimens, pharmaceutical targeting of MCL-1 with BH3-mimetics such as S63845 can act as a single-agent therapy to slow tumour growth in a syngeneic mouse model of breast cancer.